$1,000 invested in Mesoblast shares at the start of 2024 is now worth…

Did this biotech company deliver the goods for investors? Let's see what a $1,000 investment would be worth.

| More on:
Person holding Australian dollar notes, symbolising dividends.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mesoblast Ltd (ASX: MSB) shares have been on an incredible run over the past 12 months.

So much so, you would be laughing all the way to the bank if you had bought the biotechnology company's shares at the start of 2024.

Let's see what a $1,000 investment in the company's shares would be worth now.

$1,000 invested into Mesoblast shares

At the start of 2024, investors were able to pick up the company's shares for 31 cents.

This means that with a $1,000 investment, you would have ended up owning 3,226 Mesoblast shares.

Today, the stem cell therapy developer's shares are worth significantly more than the start of 2024 and closed yesterday's session at $3.06.

This means that those 3,226 shares have a market value of $9,871.56.

That's a staggering return on investment of approximately $8,871 after just a touch over 12 months.

But how did we get here? Let's dig a little deeper into things.

Why did its shares rocket?

It is worth noting that at the start of 2024, things were looking very uncertain for Mesoblast.

The company had been knocked back multiple times from the US FDA when attempting to get its stem cell therapies approved.

This led to management having to raise funds countless times over the past decade to keep the lights on. But its perseverance paid off, with regulators in the US finally changing their tune and approving its Ryoncil (remestemcel-L) product as the first mesenchymal stromal cell (MSC) therapy in the US in December last year.

Ryoncil is the only MSC therapy approved in the U.S. for any indication, and the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children two months and older. This includes adolescents and teenagers.

SR-aGvHD is a life-threatening condition with high mortality rates. Annually in the United States there are approximately 10,000 patients that undergo an allogeneic bone marrow transplant, 1,500 of whom are children.

This approval has sparked hopes that Mesoblast's other stem cell therapies could soon be approved, putting the company in a position to generate significant revenues in the coming years. Mesoblast's chief executive, Dr. Silviu Itescu, said:

With RYONCIL approval by FDA, Mesoblast has demonstrated the ability to bring the first MSC product to market. We will continue to work closely with FDA to obtain approval of our other late-stage products, including REVASCOR for cardiovascular diseases and rexlemestrocel-L for inflammatory pain indications, as well as expanding the indications for RYONCIL in both children and adults with inflammatory conditions.

Can its shares keep rising?

Bell Potter still sees scope for Mesoblast's shares to keep rising. Its analysts recently put a speculative buy rating and $3.90 price target on them. It said:

The approval of Ryoncil has been transformational for the company with an exciting pipeline of products to follow. We retain our Buy (Spec) rating with valuation increased to $3.90 (from $1.40) owing largely to the de-risking of future revenues.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Woman flexes muscles after donating blood.
Healthcare Shares

The CSL share price hit a 52-week low this week. Is it time to buy?

Is this beaten-up biotech a healthy opportunity?

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »

A man looking at his laptop and thinking.
Earnings Results

CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

Read more »